Recent Updates
Recently added Catalysts
STRO Positive Sentiment Score: 85/100

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Key Takeaway: Sutro Biopharma, Inc. announced its participation in the 15th Annual World ADC Conference, featuring five key presentations focused on advancements in antibody drug conjugates (ADCs). Key presentations include the development of dual-payload ADCs, updates on their ADC candidate targeting the folate receptor, and novel approaches to enhance therapeutic efficacy and safety. This reflects Sutro's commitment to innovation in cancer therapy and engagement with the scientific community.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sutro Biopharma presents five innovative ADC presentations at a significant conference.
  • The focus on dual-payload ADCs and site-specific conjugation indicates advanced research capabilities.
  • The company continues to show strong commitment to improving cancer therapeutics.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.
Presentation Details:
Development of Dual-Payload Antibody Drug Conjugates  Presenter: Daniel Calarese, Ph.D.
Date/Time: November 4, 2024, 2:00pm PT
Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor
Presenter: Hanspeter Gerber, Ph.D.
Date/Time: November 5, 2024, 11:30am PT
Characterizing ADC Safety & Activity in Preclinical Development of STRO-004
Presenter: Alice Yam, Ph.D.
Date/Time: November 5, 2024, 2:00pm PT
Leveraging Cell-Free Protein Synthesis for Site- Specific Conjugation to Enhance ADC Therapeutic Index
Presenter: Gang Yin, Ph.D.
Date/Time: November 5, 2024, 2:30pm PT
Optimizing High DAR & Dual Payload ADCs: Discovery of Hydrophilic β-glu Cleavable Linker Payloads for Superior Efficacy and Safety
Presenter: Krishna Bajjuri, Ph.D.
Date/Time: November 6, 2024, 3:00pm PT
Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at www.sutrobio.com.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

What is Sutro Biopharma known for?

Sutro Biopharma focuses on developing site-specific and novel-format antibody drug conjugates.

When is the 15th Annual World ADC Conference?

The conference takes place from November 4-6, 2024, in San Diego.

Who will present on Dual-Payload Antibody Drug Conjugates?

Daniel Calarese, Ph.D., will present on Dual-Payload ADCs.

Where can I find the presentations after the conference?

Presentations will be available on Sutro Biopharma's website in the Clinical/Scientific section.

What is luveltamab tazevibulin?

Luveltamab tazevibulin, or luvelta, is a folate receptor alpha-targeting ADC in clinical studies.

Last updated: Nov 4, 2024